Partnerships

Partnerships

Partnerships and License Agreements

We target product candidates for which human proof of concept exists in the intended indication, for either the target or the compound, and for which biomarkers are available to guide development. We target conditions where we believe current treatments fail to address medical needs, and where we can apply clinical strategies to increase signal detection. Successfully in-licensing product candidates that meet these criteria is critical to our success.

Lilly

Lilly

In September 2016, we entered into an exclusive worldwide license agreement with Lilly pursuant to which Lilly granted us rights relating to CERC-611, a potent and selective Transmembrane AMPA Receptor Regulatory Protein (TARP)-γ8-dependent AMPA receptor antagonist, and, any product containing CERC-611 for the prevention, diagnosis and/or treatment of human diseases. Under the terms of the agreement, Cerecor assumed full development and commercialization responsibilities of CERC-611. Lilly will receive an upfront licensing fee as well as milestone and tiered royalty payments on net sales.

In February 2015, Cerecor entered into an exclusive worldwide license agreement with Lilly to develop and commercialize CERC-501, a selective and potent kappa opioid receptor antagonist, for the prevention, diagnosis and/or treatment of human diseases. In consideration of the license agreement we are required to make an initial upfront payment, certain development and commercial milestones payments and royalties on net sales. Cerecor is responsible for development and commercialization of CERC-501 including any products that contain CERC-501

Merck

Merck

In April 2013, we entered into an exclusive worldwide license agreement with Merck to develop and commercialize CERC-301, an oral, NR2B specific NMDA receptor antagonist, for the prevention, diagnosis and/or treatment of human diseases. Under the terms of the agreement, Cerecor will be responsible for development and commercialization of CERC-301 and/or any product containing CERC-301. Merck will receive and upfront payment plus certain milestone payments and a percentage of net sales.

In March 2013, Cerecor entered into an exclusive worldwide license agreement with Merck pursuant to which Merck granted Cerecor rights to small molecule compounds known to inhibit COMT as its primary mechanism of action and any pharmaceutical product containing such compounds for the prevention, diagnosis and/or treatment of human diseases. Under the terms of the agreement, Merck is to receive an upfront licensing fee as well as milestones and tiered royalty payments. Cerecor assumes all responsibilities associated with development and commercialization of said compounds and/or products.